Dexcom, Inc., a developer of continuous glucose monitoring (CGM) systems for diabetes management, has announced the South African launch of its Dexcom G6 System for people with diabetes ages two years and up.
The Dexcom G6 is a stand-alone CGM system for multiple dose injection (MDI) therapy users, which represent the majority of the type 1 population, and can also be used by anyone on insulin pump therapy. With the G6, the sensor is worn separately from an insulin pump and is inserted under the skin to measure the level of glucose in the interstitial fluid (fluid in the tissue). The sensor is disposable and should be changed every 10 days.
The Dexcom G6 will be available in South Africa later this month and has already been introduced in the US and the UK earlier in the year.
“The Dexcom G6 represents the future of diabetes management. Not only does the product eliminate the need for fingersticks, but it also maintains the performance, connectivity and accuracy that the diabetes community has come to expect from Dexcom CGM,” said Dexcom’s General Manager for EMEA, John Lister.
According to Lister, Dexcom G6 encompasses a number of new features that empower users to take control of their diabetes. For example, other than a longer battery lifer than previous generation Dexcom CGM sensors, the new system has customisable alarms and alerts that go off to warn users and their designated followers of dangerous glucose levels, even while they are asleep – a useful feature for children and those with impaired hypoglycaemia awareness.
Continuous glucose readings are also sent automatically via Bluetooth to any compatible smart device, or to a Dexcom receiver, at five-minute intervals. Furthermore, with the Dexcom G6 app, users can share their glucose information with up to five people, enabling the user’s care team to remotely monitor the user.
“With diabetes, you become your own doctor first. You learn about your condition and understand how your body responds to medication so you are able to manage the condition properly. It is costly physically and emotionally but once you learn to manage your blood sugar, there is nothing stopping you from living a normal life,” said Ngoy Sina Ngandu, a professional living with type 1 diabetes.
“A large part of the convenience of CGM is that patients can make treatment decisions without a confirmatory fingerstick. As a small wearable device, it is discrete and can track glucose levels 24 hours a day, giving real-time alerts on smartphones if levels exceed or drop below the users defined levels. Technology has the ability to not only transform clinical diagnoses and treatments, but also empower individuals to take greater control over their own health,” continued Ngandu.
Professor David Segal from the Centre for Diabetes and Endocrinology (CDE) South Africa added: “Pain, inconvenience and lack of clarity limit the functionality of self-monitoring of blood glucose testing. Continuous glucose monitoring opens up a whole new world in diabetes management by giving high-clarity visibility of real-time blood glucose data displaying both rate and direction-of-change.”
“The ability to see where one’s blood glucose has come from and where it is heading allows for better prospection and also a tighter association between an input variable and a resultant effect on blood glucose. The Dexcom G6 requires no fingerprick calibration and its accuracy allows one to set and hit targets with more precision thereby facilitating learning and improved real-world outcomes,” concluded Professor Segal.
The Dexcom G6 received its CE Marking in June 2018, confirming that the G6 system meets the Essential Requirements of the Medical Device Directive MDD 93/42/EEC as amended by 2007/47/EC. The new system is also the first CGM system to receive the US Food and Drug Administration’s (FDA) De Novo classification. With this new classification, the Dexcom G6 CGM system is indicated for use as both a stand-alone CGM and for integration into automated insulin dosing (AID) systems.